Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin

US FDA Clears Monotherapy Use

Executive Summary

At ESMO, data showed objective response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.

You may also be interested in...



Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine

Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.

Keytruda Expands Cervical Cancer Position With ESMO Data

In addition to securing a key position in first-line disease, Keytruda has potential to expand its presence in later lines with combination data from Seagen/Genmab’s Tivdak.

GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning

US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel